share_log

B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1

B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1

B. Riley Securities将X4制药评级下调至中性,将目标股价下调至1美元
Benzinga ·  2023/12/12 08:12

B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the price target from $3 to $1.

B. Riley Securities分析师卡尔皮特·帕特尔将X4 Pharmicals(纳斯达克股票代码:XFOR)的评级从买入下调至中性,并将目标股价从3美元下调至1美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发